DSIP

Buy DSIP Online

Book Now

Questions about peptides? Click here to schedule a free consultation with a physician.

US comparison $1,743.98 Save $1,706.99
Our Price $36.99 Price Match Promise Found a lower price? We'll match it.
x
Secure Encrypted Payments

DSIP is delta sleep-inducing peptide, a synthetic nine-amino-acid neuropeptide supplied as a lyophilized research peptide. DSIP can be bought online, with the current quantity and price shown during ordering. Choose the DSIP format displayed during checkout only when it matches the intended research context, handling needs, and storage controls.

For research and analytical purposes only. Not intended for human consumption, therapeutic use, veterinary administration, diagnostic use, or clinical application.

DSIP Peptide Price, Ordering, and Use Status

The DSIP peptide price shown during ordering reflects the currently available quantity and research product format. Cost planning should account for the amount needed, reconstitution timing, storage limits after preparation, and whether the full quantity can be used under appropriate handling conditions.

DSIP is often discussed online in connection with sleep, insomnia, and stress, but those topics do not make it an approved sleep medicine, supplement, or self-directed protocol. Research peptide availability, clinical trial participation, and approved medical treatment are separate categories. This DSIP product is supplied for research and analytical use only.

People asking where to buy DSIP peptides should also consider product identity, batch information, storage instructions, and suitability for the intended non-clinical work. For broader browsing across related materials, see the peptides category.

Quick tip: Record the product name, batch information, storage conditions, and reconstitution date before handling the material.

What DSIP Is

DSIP stands for delta sleep-inducing peptide. It is a short-chain neuropeptide composed of nine amino acids and has been studied because of its possible relationship with sleep-associated physiology, circadian regulation, stress-response pathways, and neuroendocrine signaling.

The name comes from early research that connected DSIP with sleep-related biological processes. Later scientific interest broadened to regulatory signaling in the nervous and endocrine systems, including hormone-related feedback, neurotransmitter activity, and adaptive responses to stress. These remain research topics, not confirmed clinical uses.

ParameterSpecification
Product NameDSIP
Full NameDelta Sleep-Inducing Peptide
Peptide ClassNeuropeptide
Amino Acid Length9 amino acids
Molecular FormulaC35H48N10O15
Molecular Weight848.82 g/mol
Other Known TitlesDSIP nonapeptide; emideltide
Molecular TypeSynthetic peptide
AppearanceLyophilized powder
Intended UseResearch and analytical applications only

DSIP for Sleep, Insomnia, and Timing Questions

DSIP peptide for sleep is a common phrase because of the peptide’s research history. The direct answer is that DSIP has been investigated in sleep-related experimental settings, but it should not be used or presented as a treatment for insomnia, anxiety, fatigue, pain, or any medical condition.

Questions such as how long before bed to take DSIP, what DSIP dosage to use, or whether DSIP spray works are treatment-use questions. They do not have an appropriate answer for this research product. No personal dose, bedtime schedule, route of administration, or self-use protocol should be inferred from exploratory reports.

Insomnia can involve medication effects, sleep apnea, pain, mental health conditions, shift work, substance use, or other medical factors. Anyone seeking help for sleep symptoms should speak with a qualified healthcare professional rather than using research peptides. For general education separate from product use, see the insomnia information section.

Scientific Background and Research Interest

DSIP was first described in connection with naturally occurring substances associated with sleep physiology. Its exact biological role remains incompletely understood, which is why careful wording matters when discussing the peptide. Early observations may generate hypotheses, but they do not establish predictable benefit or safe personal use.

Research has examined DSIP in models involving the central nervous system, endocrine feedback loops, stress-adaptation pathways, and hormone-related signaling. These areas explore how a small peptide might interact with regulatory systems that help coordinate rest, arousal, and physiological response patterns.

  • Sleep architecture and circadian rhythm studies
  • Neuroendocrine signaling research
  • Stress-response and adaptation models
  • Central nervous system communication studies
  • Hormonal regulation investigations
  • Neurotransmitter interaction research
  • Peptide-based neurological experiments

These categories help explain why DSIP remains relevant in peptide science. They do not establish DSIP as a consumer sleep aid, wellness product, or clinically proven therapy.

Handling, Storage, and Reconstitution Considerations

DSIP is described as a lyophilized powder suitable for controlled reconstitution. Follow the product documentation and appropriate safety practices for peptide materials. Storage temperature, moisture exposure, solvent choice, container labeling, and contamination prevention can affect material integrity and the reliability of downstream work.

After reconstitution, avoid informal handling. Label prepared material clearly, record concentration and date, and use sterile or analytical technique when the intended work requires it. Peptides can be sensitive to moisture, temperature changes, repeated handling, and freeze-thaw cycles.

Prompt, express shipping may be relevant when planning receipt and storage, but safe handling after arrival remains essential. For practical context on peptide sourcing, labeling, and access boundaries, see peptide labels, safety, and access.

Safety Boundaries and Practical Cautions

DSIP is not intended for human consumption, injection, nasal use, oral use, topical application, or animal administration. Online terms such as DSIP peptide dosage, DSIP peptide protocol, DSIP spray, and DSIP for insomnia often reflect consumer curiosity, but they should not be treated as safe-use instructions.

How safe is DSIP peptide? The careful answer is that safety for personal use has not been established for this research product. Published reports vary by model, method, preparation, endpoint, and outcome. That evidence base is not a substitute for approved drug labeling, clinician monitoring, or established treatment guidelines.

Use appropriate personal protective equipment and avoid exposure through skin, eyes, inhalation, or accidental ingestion. Keep research materials away from food, household products, consumer supplements, medicines, and personal-care items. If a product is being considered for any human or veterinary purpose, that use is outside the stated purpose of this material.

For a broader safety discussion across peptide categories, see peptide risks and access. For DSIP-specific boundaries, the article on DSIP dosage, safety, and practical limits separates research planning from unsupported self-use claims.

Research Applications Under Investigation

Sleep and Circadian Rhythm Studies

DSIP has been investigated in relation to sleep-associated biological processes. Work in this area has explored whether the peptide interacts with mechanisms involved in sleep architecture, circadian timing, and neural activity during resting states.

Neuroendocrine Function Research

Neuroendocrine systems connect nervous-system signaling with hormone regulation. DSIP has been evaluated for possible interactions with pathways involved in pituitary activity, endocrine feedback, and physiological adaptation.

Stress Response Investigations

Experimental models have examined DSIP in the context of physiological and environmental stressors. The research question is whether the peptide participates in adaptive signaling networks that influence neurochemical and systemic stress responses. For condition education separate from DSIP product use, see the stress information section.

Central Nervous System Research

The central nervous system remains a major focus in DSIP research. Studies have considered potential relationships with neuronal communication, regulatory feedback, and neurotransmitter activity. Continued investigation is needed because peptide signaling in the nervous system can be complex and context-dependent.

Mechanisms Being Studied

Current scientific discussion suggests that DSIP may be involved in several biological pathways, although the details remain unsettled. Proposed areas include neuroendocrine modulation, sleep-associated regulatory systems, circadian rhythm processes, neurotransmitter activity, stress-response signaling, and hormonal feedback mechanisms.

These possible mechanisms are best understood as research hypotheses. They should not be converted into personal treatment claims. Clear endpoints help reduce overinterpretation, especially when findings come from older reports, small studies, different models, or exploratory observations.

Why it matters: A research signal is not the same as an approved indication, proven benefit, or safe personal-use direction.

Quality Considerations for DSIP Peptide

Research-grade DSIP should be evaluated for consistency, identity, and suitability for the intended non-clinical use. Batch information, storage discipline, traceable records, and appropriate documentation all support more reliable handling and interpretation.

The practical quality process continues after purchase. Keep containers closed when not in use, protect lyophilized material from avoidable moisture exposure, and avoid unnecessary freeze-thaw cycles after reconstitution if the intended workflow restricts them. Separate research peptides from any consumer, clinical, veterinary, or food-use environment.

Search interest around DSIP peptide 10mg, DSIP spray, and DSIP peptide reviews can blur different product types and claims. Product decisions should be based on the actual material supplied, its documentation, its intended use, and whether the planned work stays within research-use boundaries.

How DSIP Compares With Related Peptide Topics

DSIP is a distinct peptide with its own research history. Related peptide categories can help place it in context, but different peptides may have different amino acid sequences, stability considerations, experimental targets, handling needs, and safety boundaries.

Epithalon is another peptide topic sometimes discussed in relation to aging, circadian biology, or regulatory pathways, but it is not interchangeable with DSIP. If you are reviewing adjacent peptide materials, the Epithalon product information can help distinguish product identity and research context.

DSIP also differs from consumer sleep aids and approved insomnia medicines. Consumer products and approved medicines are evaluated through different regulatory and safety frameworks. Keeping those categories separate helps avoid unsafe assumptions and protects the credibility of research findings.

Authoritative Sources

The American Chemical Society molecule summary for DSIP describes its chemical identity. A PubMed historical review of delta-sleep-inducing peptide research summarizes early evidence. A PubMed record on DSIP in insomnia illustrates why older human reports should be read cautiously and not converted into self-use directions.

Published findings may use different models, endpoints, preparation methods, and interpretation standards. Peer-reviewed literature can inform research context, but it does not replace approved labeling, clinician care, or product-specific handling instructions.

This content is for informational purposes only and is not a substitute for professional medical advice.

Research & Education Tool

DSIP Dosage Calculator

Enter the vial amount, diluent volume, syringe size, and target amount to estimate concentration, draw volume, and approximate vial yield.

For research and educational use only. Check all values against the product label, certificate of analysis, and any applicable professional guidance before relying on the result.

mg

Concentration - mcg / mL
Volume per Dose - -
Estimated Draws / Vial - rounded down to whole draws

Click here to order.

Draw Reference

Enter values to estimate the syringe mark.

0 - - - -

Express Shipping - from $29.99

Shipping with this method takes 3-5 days

Prices:
  • Dry-Packed Products $29.99
  • Cold-Packed Products $39.99
Shipping Countries:
  • United States (all contiguous states**)
  • Worldwide (excludes some countries***)

Standard Shipping - $19.99

Shipping with this method takes 5-10 days

Prices:
  • Dry-Packed Products $19.99
  • Not available for Cold-Packed products
Shipping Countries:
  • United States (all contiguous states**)
  • Worldwide (excludes some countries***)

Rewards Program

Earn points on birthdays, product orders, reviews, friend referrals, and more! Enjoy your medication at unparalleled discounts while reaping rewards for every step you take with us.

You can read more about rewards here.

POINT VALUE

100 points
1 USD

How to earn points

  • 1Register and/or Login
    Create an account and start earning.
  • 2Earn Rewards
    Earn points every time you shop or perform certain actions.
  • 3Redeem
    Redeem points for exclusive discounts.

You Might Also Like

GHK-Cu

$47.49

  • In Stock
  • Express Shipping
Our Price $47.49
Select options This product has multiple variants. The options may be chosen on the product page
PT-141

$56.99

  • In Stock
  • Express Shipping
Our Price $56.99
Select options This product has multiple variants. The options may be chosen on the product page
Cagrilintide

$186.19

  • In Stock
  • Express Shipping
Our Price $186.19
Select options This product has multiple variants. The options may be chosen on the product page
Tesamorelin

$75.99

  • In Stock
  • Express Shipping
US $6,040.69
Our Price $75.99
Select options This product has multiple variants. The options may be chosen on the product page

Peptide Screening Form

Patient Information

Please provide your basic demographic information.

Type your date of birth in MM/DD/YYYY format.

Peptides of Interest

Peptides of Interest

Select the peptides you are interested in or have been recommended.

Medical History & Screening

Medical History & Screening

Please indicate if any of the following apply to you. Red flag alerts will appear if a condition contraindicates any of the available peptide therapies.

Contraindicated for CJC-1295: Growth hormone-releasing peptides like CJC-1295 are contraindicated in patients with active cancer because they may promote cell proliferation and tumor growth.

Contraindicated for Ipamorelin: Ipamorelin stimulates growth hormone release, which may promote tumor growth and cell proliferation in active cancers.

Contraindicated for Sermorelin: Sermorelin increases growth hormone production, which may stimulate growth of existing tumors.

Contraindicated for BPC-157: BPC-157 promotes angiogenesis (new blood vessel formation), which could support tumor growth and metastasis in active cancers.

Contraindicated for AOD-9604: Although AOD-9604 is a modified GH fragment, it may still interact with growth-related pathways in patients with active malignancies.

Contraindicated for TB-500 (Thymosin Beta-4): TB-500 promotes cell migration and angiogenesis, which may facilitate tumor growth and metastasis in active cancers.

Contraindicated for GHK-Cu: GHK-Cu promotes angiogenesis and tissue remodeling, which may support tumor growth in patients with active cancer.

Contraindicated for Epithalon (Epitalon): Epithalon stimulates telomerase activity. Cancer cells exploit telomerase to achieve immortality, potentially accelerating tumor growth.

Contraindicated for Semax: Semax has neurotrophic properties that promote cell growth, which may be concerning in patients with active malignancies.

Contraindicated for MOTS-c: MOTS-c influences cellular metabolism and AMPK pathways. Effects on cancer cell metabolism are not fully understood.

Contraindicated for Tesamorelin: Tesamorelin stimulates growth hormone release, which may promote tumor growth in patients with active malignancies.

Contraindicated for Hexarelin: Hexarelin stimulates growth hormone release, which may promote tumor growth and cell proliferation.

Contraindicated for GHRP-6: GHRP-6 stimulates growth hormone release, which may promote tumor growth in active cancers.

Contraindicated for GHRP-2: GHRP-2 stimulates growth hormone release, which may promote tumor growth in active malignancies.

Contraindicated for Melanotan II: Melanotan II stimulates melanocyte activity. In patients with skin cancers, particularly melanoma, it may accelerate disease progression.

Contraindicated for Dihexa: Dihexa activates hepatocyte growth factor (HGF) pathways, which can promote tumor growth and metastasis.

Contraindicated for Kisspeptin-10: Kisspeptin-10 influences reproductive hormone pathways. Hormone-sensitive cancers may be affected by altered GnRH and gonadotropin levels.

Contraindicated for Humanin: Humanin has anti-apoptotic properties that may protect cancer cells from programmed cell death, potentially supporting tumor survival.

Contraindicated for Retatrutide: Retatrutide acts on multiple metabolic pathways including GLP-1 and GIP receptors. Its effects on cell proliferation in patients with active malignancies have not been fully characterized.

Contraindicated for CJC-1295: CJC-1295 stimulates growth hormone release, which can increase IGF-1 levels. Elevated IGF-1 has been associated with cancer recurrence.

Contraindicated for Ipamorelin: The growth hormone and IGF-1 elevation from Ipamorelin may increase the risk of cancer recurrence.

Contraindicated for Sermorelin: Growth hormone stimulation from Sermorelin elevates IGF-1, which has been linked to increased cancer recurrence risk.

Contraindicated for BPC-157: The pro-angiogenic properties of BPC-157 may potentially support recurrence by promoting blood vessel growth that could feed dormant cancer cells.

Contraindicated for TB-500 (Thymosin Beta-4): The pro-angiogenic and cell-migration properties of TB-500 may increase the risk of cancer recurrence.

Contraindicated for Epithalon (Epitalon): Telomerase activation from Epithalon may increase the risk of cancer recurrence by supporting abnormal cell survival.

Contraindicated for Tesamorelin: Growth hormone and IGF-1 elevation from Tesamorelin may increase risk of cancer recurrence.

Contraindicated for Hexarelin: Elevated growth hormone and IGF-1 from Hexarelin may increase risk of cancer recurrence.

Contraindicated for GHRP-6: Growth hormone and IGF-1 elevation from GHRP-6 may increase risk of cancer recurrence.

Contraindicated for GHRP-2: Elevated IGF-1 from GHRP-2-stimulated growth hormone may increase cancer recurrence risk.

Contraindicated for Melanotan II: Melanocortin stimulation from Melanotan II may increase melanoma recurrence risk in patients with skin cancer history.

Contraindicated for Dihexa: HGF pathway activation from Dihexa may increase cancer recurrence risk through pro-growth signaling.

Contraindicated for Humanin: The cytoprotective effects of Humanin may increase cancer recurrence risk by inhibiting apoptosis in dormant cancer cells.

Contraindicated for Retatrutide: GLP-1 receptor agonists have been linked to thyroid C-cell tumors in animal studies. Retatrutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma.

Contraindicated for Retatrutide: Retatrutide is contraindicated in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) due to the risk of medullary thyroid carcinoma associated with GLP-1 receptor agonists.

Contraindicated for CJC-1295: CJC-1295 has not been studied in pregnancy and may affect fetal development through altered growth hormone levels.

Contraindicated for Ipamorelin: Ipamorelin has not been studied in pregnancy. Altered growth hormone levels may impact fetal development.

Contraindicated for Sermorelin: Sermorelin is not approved for use during pregnancy due to potential effects on fetal growth and development.

Contraindicated for BPC-157: BPC-157 has not been adequately studied in human pregnancy. Its tissue-modulating effects may pose risks to fetal development.

Contraindicated for Thymosin Alpha-1: Immune modulation during pregnancy may disrupt the delicate immune tolerance required for fetal development.

Contraindicated for PT-141: PT-141 is contraindicated in pregnancy as melanocortin receptor activation may affect fetal development.

Contraindicated for AOD-9604: AOD-9604 has not been studied in pregnancy. Its effects on fetal metabolism are unknown.

Contraindicated for TB-500 (Thymosin Beta-4): TB-500 has not been studied in pregnancy. Its tissue-remodeling effects may pose risks to fetal development.

Contraindicated for GHK-Cu: GHK-Cu has not been studied in pregnancy. Copper peptide effects on fetal development are unknown.

Contraindicated for Epithalon (Epitalon): Epithalon has not been studied in pregnancy. Effects on fetal cellular development are unknown.

Contraindicated for Selank: Selank has not been studied in pregnancy. Its neuroactive effects may impact fetal brain development.

Contraindicated for Semax: Semax has not been studied in pregnancy. Its neuroactive and hormonal effects may affect fetal development.

Contraindicated for DSIP (Delta Sleep-Inducing Peptide): DSIP has not been studied in pregnancy. Its neuroendocrine effects may impact fetal development.

Contraindicated for MOTS-c: MOTS-c has not been studied in pregnancy. Its metabolic effects may impact fetal development.

Contraindicated for Tesamorelin: Tesamorelin is contraindicated in pregnancy due to potential effects on fetal growth from altered growth hormone levels.

Contraindicated for Hexarelin: Hexarelin has not been studied in pregnancy. Altered growth hormone levels may impact fetal development.

Contraindicated for GHRP-6: GHRP-6 has not been studied in pregnancy. Growth hormone modulation may affect fetal development.

Contraindicated for GHRP-2: GHRP-2 has not been studied in pregnancy. Its effects on fetal growth and development are unknown.

Contraindicated for Melanotan II: Melanotan II is contraindicated in pregnancy due to unknown effects on fetal development from melanocortin receptor activation.

Contraindicated for LL-37: LL-37 has not been studied in pregnancy. Immune modulation may disrupt maternal-fetal immune tolerance.

Contraindicated for KPV: KPV has not been studied in pregnancy. Its immunomodulatory effects may impact fetal development.

Contraindicated for Dihexa: Dihexa has not been studied in pregnancy. Its neurotrophic and growth factor effects may impact fetal development.

Contraindicated for 5-Amino-1MQ: 5-Amino-1MQ has not been studied in pregnancy. Its metabolic enzyme inhibition may affect fetal development.

Contraindicated for SS-31 (Elamipretide): SS-31 has not been studied in pregnancy. Its effects on mitochondrial function in developing tissues are unknown.

Contraindicated for PE-22-28: PE-22-28 has not been studied in pregnancy. Its neurogenic effects may impact fetal brain development.

Contraindicated for Kisspeptin-10: Kisspeptin-10 directly affects reproductive hormones and GnRH signaling. Use during pregnancy may disrupt hormonal balance critical for fetal development.

Contraindicated for Humanin: Humanin has not been studied in pregnancy. Its effects on fetal cellular development and apoptosis pathways are unknown.

Contraindicated for KLOW: KLOW has not been studied in pregnancy. Effects on fetal development are unknown.

Contraindicated for GLOW: GLOW has not been studied in pregnancy. Effects on fetal development are unknown.

Contraindicated for Retatrutide: Retatrutide has not been studied in pregnancy. GLP-1 receptor agonists may affect fetal development and maternal glucose regulation.

Contraindicated for CJC-1295: Safety of CJC-1295 during breastfeeding has not been established. Growth hormone modulation could affect lactation.

Contraindicated for BPC-157: Insufficient safety data exists for BPC-157 use during breastfeeding.

Contraindicated for PT-141: Safety of PT-141 during breastfeeding has not been established.

Contraindicated for AOD-9604: Insufficient safety data for AOD-9604 during breastfeeding.

Contraindicated for Selank: Safety of Selank during breastfeeding has not been established. Neuroactive peptides may pass into breast milk.

Contraindicated for DSIP (Delta Sleep-Inducing Peptide): Safety of DSIP during breastfeeding has not been established.

Contraindicated for KPV: Safety of KPV during breastfeeding has not been established.

Contraindicated for 5-Amino-1MQ: Safety of 5-Amino-1MQ during breastfeeding has not been established.

Contraindicated for PE-22-28: Safety of PE-22-28 during breastfeeding has not been established. Neuroactive peptides may pass into breast milk.

Contraindicated for Kisspeptin-10: Kisspeptin-10 modulates reproductive hormones, which may affect lactation and hormonal balance during breastfeeding.

Contraindicated for KLOW: Safety of KLOW during breastfeeding has not been established.

Contraindicated for GLOW: Safety of GLOW during breastfeeding has not been established.

Contraindicated for Retatrutide: Safety of Retatrutide during breastfeeding has not been established. It is unknown whether the peptide is excreted in breast milk.

Contraindicated for CJC-1295: Growth hormone elevation from CJC-1295 can worsen diabetic retinopathy by promoting abnormal blood vessel growth in the retina.

Contraindicated for Ipamorelin: Elevated growth hormone from Ipamorelin can accelerate retinal neovascularization in diabetic retinopathy.

Contraindicated for GHRP-6: Elevated growth hormone from GHRP-6 can worsen diabetic retinopathy by promoting abnormal blood vessel growth.

Contraindicated for GHRP-2: Growth hormone elevation from GHRP-2 can accelerate retinal neovascularization in diabetic retinopathy.

Contraindicated for Retatrutide: Rapid improvement in glycemic control from Retatrutide may temporarily worsen diabetic retinopathy. Close ophthalmologic monitoring is recommended.

Contraindicated for CJC-1295: Growth hormone-releasing peptides can elevate intracranial pressure, worsening existing intracranial hypertension.

Contraindicated for Sermorelin: Growth hormone elevation from Sermorelin can increase intracranial pressure.

Contraindicated for Tesamorelin: Growth hormone elevation from Tesamorelin can increase intracranial pressure.

Contraindicated for CJC-1295: CJC-1295 acts on the pituitary gland. Existing pituitary disorders may lead to unpredictable or dangerous hormone responses.

Contraindicated for Ipamorelin: Ipamorelin directly stimulates the pituitary gland. Pre-existing pituitary conditions may result in adverse hormonal responses.

Contraindicated for Sermorelin: Sermorelin requires a functioning pituitary gland. Pituitary disorders may prevent proper response or cause adverse effects.

Contraindicated for DSIP (Delta Sleep-Inducing Peptide): DSIP affects neuroendocrine signaling involving the pituitary gland. Pre-existing pituitary conditions may lead to unpredictable effects.

Contraindicated for Tesamorelin: Tesamorelin acts directly on the pituitary gland. Pre-existing pituitary disorders may cause unpredictable hormonal responses.

Contraindicated for Hexarelin: Hexarelin acts on the pituitary gland. Pre-existing pituitary conditions may result in adverse hormonal responses.

Contraindicated for GHRP-6: GHRP-6 acts directly on the pituitary gland. Pre-existing disorders may cause adverse hormonal effects.

Contraindicated for GHRP-2: GHRP-2 directly stimulates the pituitary gland. Pre-existing pituitary disorders may cause unpredictable responses.

Contraindicated for Kisspeptin-10: Kisspeptin-10 stimulates the hypothalamic-pituitary axis. Pre-existing pituitary disorders may lead to unpredictable hormonal responses.

Contraindicated for Thymosin Alpha-1: Thymosin Alpha-1 stimulates T-cell activity and immune response. In patients with autoimmune conditions, this can trigger disease flares.

Contraindicated for Epithalon (Epitalon): Epithalon may modulate immune function through its effects on the pineal gland, potentially exacerbating autoimmune conditions.

Contraindicated for Melanotan II: Melanotan II modulates immune function through melanocortin receptors, potentially exacerbating autoimmune conditions.

Contraindicated for LL-37: LL-37 is a potent immune activator. In autoimmune conditions, it may trigger inflammatory flares and worsen disease activity.

Contraindicated for KLOW: Peptide blends may modulate immune function. Patients with autoimmune conditions should consult their provider before use.

Contraindicated for GLOW: Peptide blends may modulate immune function. Patients with autoimmune conditions should consult their provider before use.

Contraindicated for Thymosin Alpha-1: Thymosin Alpha-1 enhances immune function, which directly counteracts immunosuppressive therapy required to prevent organ rejection.

Contraindicated for LL-37: LL-37 enhances immune function, which may counteract immunosuppressive therapy in transplant recipients.

Contraindicated for PT-141: PT-141 affects blood pressure and cardiovascular function. Patients with heart disease face increased risk of adverse cardiac events.

Contraindicated for Hexarelin: Hexarelin has been shown to affect cardiac function and cortisol release. Patients with cardiovascular disease should use caution.

Contraindicated for Melanotan II: Melanotan II affects cardiovascular function and can cause nausea and flushing. Heart disease patients should avoid use.

Contraindicated for PT-141: PT-141 can cause transient increases in blood pressure. Uncontrolled hypertension increases the risk of cardiovascular events.

Contraindicated for Semax: Semax can influence blood pressure regulation. Patients with uncontrolled hypertension should use caution.

Contraindicated for Melanotan II: Melanotan II can cause blood pressure fluctuations. Patients with uncontrolled hypertension face increased cardiovascular risk.

Contraindicated for Dihexa: Dihexa may influence cardiovascular function. Patients with uncontrolled hypertension should exercise caution.

Contraindicated for AOD-9604: Patients with severe kidney disease may have impaired clearance of AOD-9604 metabolites.

Contraindicated for MOTS-c: Patients with severe kidney disease may have impaired clearance of MOTS-c metabolites.

Contraindicated for 5-Amino-1MQ: Patients with kidney disease may have impaired clearance of 5-Amino-1MQ metabolites.

Contraindicated for SS-31 (Elamipretide): Patients with severe kidney disease may have impaired clearance of SS-31 and its metabolites.

Contraindicated for Retatrutide: Patients with severe kidney disease may have impaired clearance of Retatrutide. Dose adjustment or avoidance may be necessary.

Contraindicated for GHK-Cu: Copper metabolism is heavily dependent on liver function. Patients with liver disease may accumulate copper to toxic levels.

Contraindicated for 5-Amino-1MQ: 5-Amino-1MQ affects metabolic enzyme pathways. Patients with liver disease may experience altered drug metabolism and increased toxicity risk.

Contraindicated for Retatrutide: Retatrutide is metabolized hepatically. Patients with significant liver impairment may experience altered drug levels and increased risk of adverse effects.

Contraindicated for Retatrutide: GLP-1 receptor agonists, including Retatrutide, have been associated with an increased risk of pancreatitis. Patients with a history of pancreatitis should avoid use.

Contraindicated for BPC-157: BPC-157 affects the nitric oxide system and may influence blood clotting. Patients with clotting disorders should avoid use.

Contraindicated for TB-500 (Thymosin Beta-4): TB-500 can influence blood clotting pathways. Patients with clotting disorders or on anticoagulants should avoid use.

Contraindicated for Selank: Selank is derived from tuftsin, which can influence immune and coagulation pathways. Patients with clotting disorders should use caution.

Contraindicated for SS-31 (Elamipretide): SS-31 has been associated with injection site reactions. Patients with known peptide allergies should be monitored.

Contraindicated for KLOW: Multi-component peptide blends carry increased risk of allergic reactions. Patients with known peptide allergies should be monitored.

Contraindicated for GLOW: Multi-component peptide blends carry increased risk of allergic reactions. Patients with known peptide allergies should be monitored.

Contraindicated for Thymosin Alpha-1: Thymosin Alpha-1 directly opposes immunosuppressive medications, potentially causing dangerous drug interactions.

Contraindicated for LL-37: LL-37 stimulates immune responses, potentially opposing immunosuppressive medications.

Contraindicated for KPV: KPV has anti-inflammatory and immune-modulating effects that may interact with immunosuppressive medications.

Current Medications

List all medications, supplements, and treatments you are currently using.

Additional Notes

Medical Disclaimer

This screening questionnaire is for informational and pre-consultation purposes only. It does not constitute medical advice, diagnosis, or a treatment recommendation.

All peptide therapy protocols must be prescribed and supervised by a licensed healthcare provider. The contraindication information provided here is based on general clinical guidelines and may not reflect every individual’s unique medical circumstances.

Peptide therapies are used off-label in many cases. Results vary by individual. Borderfreehealth.com does not guarantee outcomes from any peptide therapy program.

By submitting this form, you acknowledge that a qualified medical professional will review your responses and determine appropriate treatment options. Do not discontinue any current medications or begin any new treatment based solely on the results of this screening.